Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel vs Cisplatin with IMRT in High-risk Oral Cavity Cancer
NCT02923258Phase 3Completed
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Apr 2018
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel in oral cavity squamous cell carcinoma (OCSCC) (2 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Disease-free survival at 2 years. Started Apr 2018; status: completed.
02
Drugs
docetaxel
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)
Beyond the preview
Go deeper on NCT02923258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02923258.